Today we reported third quarter financial results and provided recent corporate updates. Learn more about our pipeline progress and upcoming anticipated milestones: l1nq.com/q6jsw23 #TCRT #CellTherapy #InVivo
74
TScan’s Killer T’s wrapped up another successful season! The Killer T’s secured 2nd place in the Mass Biotech Softball League’s Metro Central Division! Made up of TScanners from across departments and levels, the team brought collaboration onto the field. Congrats Killer T's!
92
Today we reported second quarter financial results and provided recent corporate updates. Learn more about our pipeline progress and upcoming anticipated milestones: bit.ly/3SpxqMK #TCells #CellTherapy
81
Why T cell receptor (TCR)-engineered T cell (TCR-T) Therapy? Did you know TCR-T therapy builds on the remarkable success of anti-cancer immunotherapy while addressing key limitations? Learn more about our approach on our recently re-vamped website: bit.ly/3RxYkBT#DYK
4
361
Today we announced that the first patient has been dosed in the pivotal ALLOHA-2™ Phase 3 trial evaluating TSC-101 in patients with #AML and #MDS undergoing allogeneic stem cell transplant. Learn more: bit.ly/4xf08il #CellTherapy #TCells
3
261
Unfortunately, 38-44%* of patients will relapse within two years following an allogeneic stem cell transplant. TScan is developing therapies for patients following transplant to target residual cancer cells and prevent relapse. Learn more: bit.ly/4aZ6v0t #DYK #TCells
105
In recognition of #NationalCancerSurvivorMonth, we honor the strength and resilience of cancer survivors and acknowledge the caregivers, families, researchers, and clinicians who support them. We are proud to work toward a future with more survivorship stories.
Today we announced our agreement with Cellares to evaluate automated manufacturing of TSC-101 for patients with heme malignancies. Read more here: shorturl.at/YQdPL
1
66
TScan launched our new corporate website!
The updated site reflects how far we’ve come, with a sharper, more dynamic experience that matches the momentum behind our science and programs.
Take a look: tscan.com
#Tcells #CellTherapy
🤖 Made with AI
41
This month, #TScanners came together as TSpinners to ride for a cause that's close to our hearts! We raised over $23,000 participating in Cycle for Survival, the official rare cancer fundraising program of MSK Cancer Center #CycleForSurvival #RareCancer #MSK
247
Today we announced that the Company will participate in a fireside chat at the @HCWCO 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:00 a.m. ET. Learn more: bit.ly/4k0lnP1 #CellTherapy #TCells
1
211
Honoring women and girls in science today and every day! At TScan, we celebrate the talented women driving progress in science. #WomenInScience #GirlsInSTEM
7
1
155
On #WorldCancerDay, we reflect on our Mission Wall and the submissions from our #TScanners that tell a personal story of how cancer has impacted their lives, reminding us that we are #UnitedByUnique. More about our programs targeting various cancers: bit.ly/4bdd4dp
130
We look forward to being in San Francisco next week during #JPM2025! Connect with us to learn more about our recent progress and exciting plans for 2025. #CellTherapy #TCells #Biotech
139
Today we announced that we have entered into a $30 million registered direct offering at a 37% premium with Lynx1 Capital Management and an investment fund advised by Lynx1. Read the press release to learn more: bit.ly/4gu5fTv #CellTherapy #Biotech
2
230
Today we announced updated data from the ongoing ALLOHA™ Phase 1 heme trial being presented in an oral session at #ASH24. Read the press release to learn more and join our virtual KOL event tomorrow where we will discuss these data. bit.ly/4gqzydz
1
154
We’ll be presenting preliminary results from the ALLOHA™ Phase 1 trial of TSC-100 and TSC-101 in #AML, #ALL, and #MDS at #ASH24. Join our virtual KOL event on 12/10 at 8am ET, where we'll discuss the data presented at ASH and more! Register here: bit.ly/4gc97YU
1
175
For the third year, we’re one of @BostonGlobe’s 2024 Top Places to Work! This achievement reflects our commitment to creating an inclusive environment and dedication to improving the lives of patients with #Cancer. Thank you to our team! bit.ly/49mdxKq
1
105
Yesterday we announced we’ll host a virtual KOL event on 12/10 at 8am ET to discuss data from the ALLOHA™ Phase 1 trial presented at #ASH24, our clinical development strategy for the heme program and an update on the PLEXI-T™ Phase 1 solid tumor trial. bit.ly/4ghDzkx
1
149






















